Vertex Pharmaceuticals’ Cahill: One-Size-Fits-All CEA ‘Not Adequate for Every Medicine’

June 3, 2020

Vertex Pharmaceuticals VP and head of HEOR Jaime Cahill in a recent Health Affairs blog post says current cost-effectiveness evaluation methods “often fail to capture unique attributes and circumstances.”

When standard evaluation methods are applied to the unique attributes that arise in precision medicine, Cahill writes, the results often fail to “adequately reflect the real-world value these medicines may provide to patients.”

“As medicine evolves, and new ways of treating people become available, it is important to discuss whether traditional cost-effectiveness frameworks are appropriate for all situations, so policy makers and other stakeholders can make informed and evidence-based decisions,” Cahill writes.

To read the full blog post, click here.

Share This Story!